摘要
目的观察分析阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效及其对血清C反应蛋白(CRP)水平的影响。方法随机将85例肺炎支原体肺炎患儿随机分为观察组43例和对照组42例。对照组给予阿奇霉素序贯疗法,观察组给予阿奇霉素序贯疗法和孟鲁司特钠联合治疗。疗程结束后分析两组临床治疗效果、临床症状和体征(喘憋、湿啰音、咳嗽)消失时间、平均退热时间、平均住院时间、CRP水平和药物安全性。结果治疗后观察组临床总有效率明显高于对照组(95.3%vs.78.6%),差异具有显著性(P<0.05)。观察组临床症状和体征消失时间明显短于对照组,差异具有显著性(P<0.05)。且观察组平均退热时间和住院时间也明显短于对照组,差异具有显著性(P<0.05)。治疗治疗后两组CRP水平有明显降低,且观察组降低更明显,与对照组治疗后比较,差异具有显著性(P<0.05)。两组均未见严重不良反应。结论阿奇霉素和盂鲁司特钠联合使用治疗小儿支原体肺炎临床效果满意,能有效降低CRP,快速缓解患儿临床症状和体征,安全性好,值得临床推广应用。
Objective To observe and analyse the effect of azithromycin combined with montelukast in therapy of mycoplasma pneumoniae pneumonia in children and reactive protein levels of serum C. Methods Eighty - five cases of mycoplasma pneumonia in children were randomly divided into observation group(42 cases)and control group(43 cases). The control group was given azithromycin sequential therapy,while the observation group was given azithromycin combined with montelukast. The clinical outcomes,clinical signs and symptoms(wheezing,crackles, cough)disappeared time,cooling time,the average length of hospital stay,CRP levels and drug safety were analyzed after the end of treatment in two groups. Resluts The total clinical efficiency in observation group after treatment was significantly higher than that of control group(95. 3%vs. 78. 6% )( P ﹤ 0. 05). The clinical symptoms and signs disappeared time and cooling time,the average hospital stay in observation group was significantly shorter than those of control group( P ﹤ 0. 05). Comparison of therapeutic effects after treatment,CRP levels were significantly re-duced in two groups,and the observation group significantly reduced( P ﹤ 0. 05). No serious adverse reactions were found in two groups. Con-clusion Azithromycin combined with montelukast have significant clinical effect on mycoplasma pneumoniae pneumonia in children,can effective-ly reduce CRP,relieve rapidly of clinical symptoms and signs. It was worthy of clinical application.
出处
《临床和实验医学杂志》
2015年第1期41-43,共3页
Journal of Clinical and Experimental Medicine